Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 4:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 33,093 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: PLACEBO Clear all
Completed Phase 3 Interventional Accepts healthy volunteers

The Effects of Combination Zonisamide and Bupropion on Switching to an Electronic Cigarette

NCT05205811
View directory record Official record
Conditions
Smoking Cessation
Interventions
Bupropion, Zonisamide, Placebo bupropion, Placebo zonisamide, E-cigarette
Drug · Other
Lead sponsor
Rose Research Center, LLC
Industry
Eligibility
21 Years to 65 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
2
States / cities
Charlotte, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 25, 2026, 4:15 AM EDT
Completed Phase 2 Interventional Results available

A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus

NCT04535544
View directory record Official record
Conditions
Hepatitis D, Chronic
Interventions
JNJ-73763989, Placebo, Entecavir (ETV) monohydrate, Tenofovir disoproxil, Tenofovir alafenamide (TAF)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
2
States / cities
Redwood City, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 25, 2026, 4:15 AM EDT
Withdrawn Phase 2 Interventional

Safety and Efficacy of IONIS-FB-Lrx in up to 120 Patients 55 and Older With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

NCT03446144
View directory record Official record
Conditions
Geographic Atrophy, Age Related Macular Degeneration
Interventions
IONIS-FB-Lrx, Placebo (sterline saline 0.9%)
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
55 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
24
States / cities
Phoenix, Arizona • Beverly Hills, California • Encino, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Oct 25, 2026, 4:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

CC100: Safety and Tolerability of Single Doses

NCT02050334
View directory record Official record
Conditions
Healthy
Interventions
CC100, Placebo
Drug
Lead sponsor
Chemigen, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Oct 25, 2026, 4:15 AM EDT
Completed Phase 2 Interventional

A Trial In Diabetic Patients To Assess Effect Of CE-326,597 On Glucose Control And Body Weight

NCT00542009
View directory record Official record
Conditions
Weight Management, Treatment Of Obesity
Interventions
CE-326,597 100 mg QD, CE-326,597 50 mg QD, CE-326,597 25 mg QD, Placebo, CE-326,597 5mg QD
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
30
States / cities
Phoenix, Arizona • Fresno, California • National City, California + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2012 · Synced Oct 25, 2026, 4:15 AM EDT
Terminated Phase 2 Interventional

Phase 2 Study to Determine if RTB101 Reduces the Severity of COVID-19 in Older Adults Residing in Nursing Homes

NCT04409327
View directory record Official record
Conditions
COVID19
Interventions
RTB101, Placebo
Drug
Lead sponsor
Restorbio Inc.
Industry
Eligibility
65 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Middletown, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Oct 25, 2026, 4:15 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of Moxidectin in Adults With Scabies

NCT05875441
View directory record Official record
Conditions
Scabies
Interventions
Moxidectin Oral Product, Placebo
Drug
Lead sponsor
Medicines Development for Global Health
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
5
States / cities
Los Angeles, California • Miami, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 25, 2026, 4:15 AM EDT
Completed Phase 2 Interventional Results available

A Study of N-Acetyl Cysteine in Children With Autism

NCT00627705
View directory record Official record
Conditions
Autistic Disorder
Interventions
N-Acetyl Cysteine, Placebo - sugar pill
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
3 Years to 12 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 18, 2017 · Synced Oct 25, 2026, 4:15 AM EDT
Not listed Phase 1 Interventional

Regenerative Medicine for COVID-19 and Flu-Elicited ARDS Using Lomecel-B (RECOVER)

NCT04629105
View directory record Official record
Conditions
ARDS, Human, Covid19
Interventions
Longeveron Mesenchymal Stem Cells (LMSCs), Placebo
Biological · Other
Lead sponsor
Longeveron Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
3
States / cities
Miami, Florida • Baltimore, Maryland • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 25, 2026, 4:15 AM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate Efficacy and Safety of Light Dose in Subjects With PWB Treated With Hemoporfin PDT

NCT05171894
View directory record Official record
Conditions
Port-wine Birthmarks, Port-Wine Stain, Nevus Flammeus
Interventions
Hemopfin+Green Light, Vehicle+Green Light
Drug · Device
Lead sponsor
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
5
States / cities
Irvine, California • San Diego, California • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 25, 2026, 4:15 AM EDT
Recruiting Phase 2 Interventional

IVIG in the Treatment of Autoimmune Small Fiber Neuropathy With TS-HDS, FGFR-3, or Plexin D1 Antibodies

NCT04153422
View directory record Official record
Conditions
Small Fiber Neuropathy, Autoimmune Small Fiber Neuropathy, Inflammatory Polyneuropathy, Immune-Mediated Neuropathy
Interventions
Panzyga IVIG, Placebo
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Glenview, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 25, 2026, 4:15 AM EDT
Terminated Phase 4 Interventional Results available

Effect of Saxagliptin Treatment on Myocardial Fat Content, and Monocyte Inflammation

NCT01548651
View directory record Official record
Conditions
Impaired Glucose Tolerance
Interventions
Saxagliptin, Placebo
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
30 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 25, 2026, 4:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Investigate the Effects of CBP-307 on the Heart Rate-corrected QT Interval (QTc) in Healthy Subjects

NCT04818229
View directory record Official record
Conditions
Autoimmune Diseases
Interventions
CBP-307, Placebo-matched CBP-307, Moxifloxacin (Avelox), Placebo-matched Moxifloxacin
Drug
Lead sponsor
Connect Biopharma Australia Pty Ltd
Industry
Eligibility
18 Years to 60 Years
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Hialeah, Florida
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Oct 25, 2026, 4:15 AM EDT
Completed Phase 2 Interventional Results available

Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Chronic Pruritus of Unknown Origin

NCT03841331
View directory record Official record
Conditions
Pruritus
Interventions
5 mg Serlopitant Tablets, Matching Placebo Tablets
Drug
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
18 Years to 120 Years
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
41
States / cities
Hot Springs, Arkansas • Bakersfield, California • Fremont, California + 36 more
Source: ClinicalTrials.gov public record
Updated May 20, 2021 · Synced Oct 25, 2026, 4:15 AM EDT
Completed Phase 2 Interventional Results available

Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir

NCT02511431
View directory record Official record
Conditions
Hepatitis D
Interventions
Lonafarnib, Ritonavir, Placebo
Drug · Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 25, 2018 · Synced Oct 25, 2026, 4:15 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Adults 60 Through 64 Years of Age

NCT03313037
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
Multivalent, Prevnar 13, PPSV23, Saline
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
60 Years to 64 Years
Enrollment
444 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
14
States / cities
Anaheim, California • Coral Gables, Florida • DeLand, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2019 · Synced Oct 25, 2026, 4:15 AM EDT
Completed Phase 2 Interventional

The Health-Promoting Role of Pears in Men and Women With Metabolic Syndrome

NCT02228837
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
Pear, Placebo
Dietary Supplement
Lead sponsor
Florida State University
Other
Eligibility
45 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Dec 8, 2016 · Synced Oct 25, 2026, 4:15 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Study of Inhaled Nitric Oxide (iNO) and Respiratory Outcomes in Late Preterm Infants

NCT01748045
View directory record Official record
Conditions
Bronchopulmonary Dysplasia
Interventions
inhaled nitric oxide, Placebo Comparator - nitrogen gas
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
30 Weeks to 36 Weeks
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 19, 2017 · Synced Oct 25, 2026, 4:15 AM EDT
Completed Phase 3 Interventional Results available

Buprenorphine for Treatment Resistant Depression

NCT01407575
View directory record Official record
Conditions
Depression, Depressive Disorder, Depressive Disorder, Major
Interventions
Buprenorphine, Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
21 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 9, 2018 · Synced Oct 25, 2026, 4:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study to Evaluate the Efficacy of EZC Pak in Adults With Upper Respiratory Infection (URI)

NCT04943575
View directory record Official record
Conditions
Common Cold
Interventions
EZC Pak, EZC Pak +D, Placebo
Dietary Supplement
Lead sponsor
PPC Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Apr 7, 2022 · Synced Oct 25, 2026, 4:15 AM EDT
Completed Phase 3 Interventional

Fenretinide in Treating Patients With Cervical Neoplasia

NCT00003075
View directory record Official record
Conditions
Cervical Cancer, Precancerous Condition
Interventions
Fenretinide, Placebo
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2001
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Oct 25, 2026, 4:15 AM EDT
Completed Not applicable Interventional Results available

A Study of Hyaluronate Injectable Viscosupplement for Treatment of Osteoarthritis of the Knee

NCT02495857
View directory record Official record
Conditions
Osteoarthritis
Interventions
Hyaluronate Injectable Viscosupplement, Euflexxa IA injection, Placebo
Device
Lead sponsor
Actavis Inc.
Industry
Eligibility
40 Years and older
Enrollment
599 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
San Diego, California • Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jun 23, 2020 · Synced Oct 25, 2026, 4:15 AM EDT
Completed Phase 2 Interventional Results available

LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)

NCT04402957
View directory record Official record
Conditions
COVID, Severe Acute Respiratory Syndrome, Sars-CoV2, Acute Kidney Injury, Acute Respiratory Distress Syndrome
Interventions
LSALT peptide, Placebo
Drug
Lead sponsor
Arch Biopartners Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
San Diego, California • Fort Lauderdale, Florida • Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 9, 2025 · Synced Oct 25, 2026, 4:15 AM EDT
Recruiting Phase 2 Interventional

Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis

NCT07029581
View directory record Official record
Conditions
Lewy Body Dementia Psychosis
Interventions
ACP-204, Placebo
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
55 Years to 84 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
30
States / cities
Irvine, California • Aurora, Colorado • Washington D.C., District of Columbia + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 25, 2026, 4:15 AM EDT